Session 1: Artificial Intelligence & Cancer

Using AI to Enhance Care of Glioblastoma Patients

Glioblastoma is a highly aggressive and malignant form of brain cancer, characterized by poor prognosis and limited treatment options. Despite advances in medical research, the disease remains a significant challenge, with a high recurrence rate and short overall survival. To improve patient outcomes, IRT Saint Exupéry and Oncopole Claudius Regaud (OCR) have been collaborating for four years to leverage artificial intelligence (AI) in glioblastoma care.



Our research has focused on developing AI models that can analyze multimodal data, including MRI scans, whole-slide images (WSI), and RNA-seq data. These models have demonstrated the ability to predict key clinical endpoints, such as overall survival (OS) and progression-free survival (PFS), allowing for more accurate prognosis and personalized treatment planning. Furthermore, our AI algorithms can identify key biological pathways involved in glioblastoma aggressiveness, providing valuable insights into the underlying mechanisms of the disease.



This talk will present our latest findings on the application of AI in glioblastoma care, highlighting the potential of machine learning to enhance patient outcomes and improve our understanding of this complex disease. By combining cutting-edge AI techniques with rich clinical data, we aim to pave the way for more effective treatment strategies and improved quality of life for glioblastoma patients.